traumat
brain
injuri
tbi
lead
caus
death
disabl
among
young
adult
us
tbi
call
silent
epidem
rel
young
victim
mean
year
age
pose
tremend
burden
famili
societi
term
year
lost
product
increas
demand
healthcar
accord
world
health
organ
tbi
becom
world
lead
caus
neurolog
disabl
across
age
group
patholog
tbi
describ
primari
injuri
result
mechan
damag
neural
vascular
structur
togeth
progress
cascad
molecular
secondari
event
lead
secondari
impair
function
damag
brain
structur
promot
cell
whilst
improv
emerg
respons
time
increas
tbi
surviv
necess
discov
reliabl
marker
identifi
patient
risk
develop
secondari
injuri
thu
requir
activ
monitor
intervent
remain
signific
challeng
current
reliabl
indic
prognosi
exist
use
tbi
glasgow
coma
scale
gc
pupil
reactiv
head
comput
tomographi
ct
indic
proven
use
patient
stratif
limit
use
predict
develop
secondari
injuri
event
particularli
true
patient
mild
tbi
mtbi
repres
approxim
tbi
case
postconcuss
symptom
includ
headach
sleep
disturb
nausea
impair
attent
memori
problem
may
develop
mention
due
limit
patient
follow
thu
urgent
need
identifi
biomark
assist
patient
diagnosi
prognosi
correl
biolog
respons
injuri
easili
measur
noninvas
manner
sampl
peripher
blood
final
detect
earli
tbi
order
predict
probabl
onset
secondari
damag
date
major
tbi
biomark
research
focus
protein
profil
bb
isozym
creatin
kinas
ckbb
glial
fibrilari
acid
protein
gfap
myelin
basic
protein
mbp
neuronspecif
enolas
nse
studi
potenti
candid
biomark
tbi
albeit
limit
use
discrimin
patient
vulner
secondari
advers
outcom
accordingli
mani
studi
fail
show
reproduc
result
candid
biomark
tbi
particularli
case
polytrauma
protein
brain
specif
may
deriv
sever
extracrani
howev
promis
axon
injuri
biomark
includ
neurofila
light
perform
better
candid
biomark
mention
previous
abl
correl
clinic
find
predict
clinic
outcom
demonstr
within
minut
traumat
impact
robust
inflammatori
respons
elicit
injur
neuroinflamm
respons
benefici
detriment
effect
contribut
secondari
brain
damag
also
facilit
neurorepair
reason
inflammatori
molecul
could
satisfi
three
main
characterist
requir
biomark
diagnosi
prognosi
tbi
particular
identif
earli
phase
severityrel
inflammatori
biomark
could
permit
clinician
recognis
treat
patient
risk
secondari
neural
damag
still
capabl
respond
therapi
irrevers
damag
occur
addit
abl
stratifi
patient
injuri
sever
risk
secondari
damag
would
also
avoid
use
unnecessari
medic
surgic
intervent
patient
tbi
novel
studi
identifi
biomark
tbi
differ
time
point
includ
sampl
collect
within
hour
injuri
prehospit
clinic
team
scene
injuri
prior
transfer
region
major
trauma
centr
mtc
use
panel
inflammationassoci
human
protein
screen
simultan
use
proseek
multiplex
inflamm
assay
serum
biomark
analys
patient
mild
tbi
mtbi
extracrani
injuri
ec
sever
tbi
stbi
ec
ec
group
compar
control
patient
healthi
volunt
hv
ec
injuri
group
inflammatori
protein
measur
significantli
separ
anova
across
time
tabl
protein
protein
tempor
separ
within
ec
group
demonstr
time
cours
differ
protein
level
serum
hv
tbi
patient
five
protein
fig
cub
domain
contain
protein
p
cc
motif
chemokin
ligand
p
interleukin
receptor
beta
p
cc
motif
chemokin
ligand
p
interleukin
p
anova
yield
significantli
separ
protein
time
point
compar
hv
mtbiec
tabl
stbiec
tabl
group
respect
protein
mtbiec
stbiec
group
also
detect
tempor
differ
ec
group
therefor
suitabl
detect
earli
inflammatori
biomark
sever
tbi
look
tempor
chang
separ
group
p
tumour
necrosi
factor
superfamili
member
trail
p
fig
c
demonstr
peak
level
hr
two
protein
found
demonstr
tempor
chang
exclus
tbi
group
although
neither
protein
could
discrimin
mtbiec
stbiec
tabl
c
tempor
express
trail
alter
ec
injuri
group
exclus
stbiec
group
protein
level
found
significantli
differ
time
yield
candid
cohort
biomark
stbi
tabl
stbi
biomark
fig
stem
cell
factor
scf
p
p
cystatin
p
osteoprotegerin
opg
p
delta
notchlik
epiderm
growth
factorrel
receptor
dner
p
leukemia
inhibitori
factor
lif
p
cell
surfac
glycoprotein
isoform
p
p
adenosin
deaminas
ada
p
p
tnfbeta
tnfb
p
p
hr
protein
differenti
express
hv
injuri
group
tabl
protein
evidenc
tabl
potenti
biomark
stbiec
serum
level
increas
stbi
p
compar
level
patient
diagnos
mtbiec
furthermor
highest
level
within
hr
sampl
fig
level
also
rais
still
higher
mtbi
p
hr
time
point
differ
hv
hr
time
point
fig
interestingli
significantli
differ
protein
detect
within
hr
time
point
across
injuri
hv
group
tabl
also
present
panel
protein
differenti
express
across
time
point
tabl
particular
exclus
found
serum
hr
time
point
increas
level
stbiec
group
compar
level
hv
p
mtbiec
group
howev
protein
significantli
differ
ec
either
tbi
injur
group
fig
hr
time
point
serum
protein
significantli
differ
hv
injuri
group
tabl
tnfb
p
p
scf
p
correl
presenc
tbi
also
sever
tbi
fig
tnfb
level
show
differ
hv
ec
group
p
ec
stbiec
group
p
mtbiec
stbiec
group
p
differ
serum
level
hv
mtbiec
patient
p
hv
stbiec
patient
p
ec
mtbiec
patient
p
demonstr
differ
express
injuri
group
hv
tbi
group
fig
serum
level
decreas
ec
p
mtbiec
p
stbiec
p
compar
hv
howev
differ
ec
mtbiec
stbiec
suggest
tnfb
ideal
biomark
tbi
fig
scf
level
lower
hv
ec
p
stbiec
p
injuri
group
interestingli
level
scf
differ
hv
mtbiec
p
injur
patient
fig
paper
analys
express
profil
panel
differ
inflammatori
protein
differ
time
point
follow
differ
grade
brain
injuri
extracrani
injuri
although
inflammatori
reaction
trigger
within
second
minut
traumat
insult
well
describ
better
understand
magnitud
time
durat
express
inflammatori
mediat
might
abl
provid
inform
natur
extent
brain
injuri
also
may
reflect
complex
subsequ
tissu
respons
deriv
multipl
insult
neuroinflamm
acut
stage
tbi
mobil
immun
cell
astrocyt
chemokin
toward
site
injuri
mount
antiinflammatori
respons
howev
excess
activ
inflammatori
molecul
contribut
secondari
cell
death
modul
inflammatori
element
proinflammatori
antiinflammatori
consid
suitabl
futur
strategi
therapeut
among
protein
analys
studi
sever
tbirel
cytokin
previous
well
character
term
potenti
role
neuron
respons
potenti
act
biomark
extent
natur
injuri
includ
date
consid
promis
molecul
sinc
fold
chang
readili
measur
serum
follow
moreov
level
previous
correl
chang
polytrauma
patient
extracrani
injuri
demonstr
effect
signific
confound
data
hr
sampl
show
serum
level
also
significantli
differenti
express
patient
extracrani
injuri
particular
result
show
serum
abl
discrimin
mtbi
ec
stbi
ec
patient
mtbi
ec
ec
data
shown
hr
express
increas
significantli
stbiec
compar
mtbiec
ec
group
hr
level
similar
injuri
group
data
shown
thu
repres
ideal
ultraearli
tbi
biomark
tabl
present
panel
inflammatori
protein
significantli
express
serum
patient
across
time
point
injuri
group
injuri
group
specif
time
point
understand
kinet
protein
potenti
discrimin
three
group
patient
potenti
identifi
biomark
tbi
particular
mtbiec
group
trail
fig
demonstr
spike
level
within
first
hour
injuri
follow
steadi
declin
time
ec
group
trail
show
signific
tempor
chang
cytoplasm
protein
neg
regul
wnt
signal
pathway
wherebi
induc
apoptosi
alter
wnt
signal
control
inflamm
wound
may
particularli
import
case
tbi
earli
spike
ie
prehospit
set
could
result
higher
level
neuron
cell
death
later
via
neg
effect
wnt
trail
protein
induc
apoptosi
via
activ
also
activ
pathway
induc
inflammatori
alter
cellular
enhanc
synapt
plastic
memori
therefor
case
tbi
decreas
level
trail
time
may
result
neuron
deficit
result
reduct
signal
stbiec
group
cohort
consist
trail
scf
opg
dner
lif
ada
tnfb
differenti
express
time
similar
mtbiec
group
signific
increas
trail
within
first
hour
injuri
fig
follow
steadi
declin
time
howev
abil
discrimin
mtbi
stbi
evid
studi
therefor
may
prove
use
prehospit
biomark
brain
trauma
gener
among
cohort
protein
differenti
express
stbiec
show
best
characterist
earli
biomark
tbi
easili
differenti
sever
tbi
howev
discrimin
three
group
mtbi
ec
ec
hv
nevertheless
earli
detect
earli
serum
sampl
make
protein
strong
candid
biomark
determin
tbi
use
conjunct
clinic
observ
inhibitor
lysosom
secret
cystein
origin
purifi
inhibit
prolifer
migrat
invas
colon
carcinoma
cell
indic
tumor
suppressor
activ
unrel
proteas
transcriptom
analysi
also
show
cystatin
might
alter
gene
express
includ
gene
encod
transcript
factor
besid
rel
undefin
role
novelti
result
report
focuss
clear
associ
tbi
except
trail
candid
biomark
stbi
group
evid
differ
hr
time
point
therefor
suitabl
detect
tbi
ultraearli
time
point
earli
object
prehospit
detect
tbi
would
support
clinic
decis
make
correct
triag
major
trauma
countri
us
uk
involv
deliv
signific
neurotrauma
case
trauma
centr
neurosurg
facil
oppos
local
trauma
unit
moreov
correct
diagnosi
tbi
one
hardest
diagnosi
make
medicin
would
allow
clinician
implement
strategi
reduc
secondari
brain
injuri
earli
stage
eg
optimis
blood
oxygen
deliveri
brain
avoid
manoeuvr
could
potenti
increas
intracrani
pressur
addit
potenti
implic
drug
develop
novel
compound
could
given
immedi
injuri
potenti
commenc
roadsid
suffici
confid
diagnosi
tbi
conclus
paper
describ
trail
potenti
biomark
tbi
demonstr
abil
differenti
sever
brain
injur
patient
either
mild
brain
injuri
within
first
hour
trail
abl
discrimin
tbi
sever
within
first
hour
highlight
trail
new
tbi
biomark
worthi
investig
describ
panel
marker
behav
hour
period
although
proseek
multiplex
inflamm
assay
suitabl
point
care
test
devic
show
ideal
ultraearli
biomark
abil
determin
presenc
tbi
discrimin
tbi
sever
may
use
aid
prehospit
team
road
side
new
portabl
devic
develop
addit
trail
abil
show
presenc
tbi
also
undergo
interrog
search
reliabl
roadsid
pitchsid
investig
diagnos
tbi
studi
particip
recruit
surgic
reconstruct
microbiolog
research
centr
srmrc
queen
elizabeth
hospit
birmingham
uk
part
reco
ethic
ref
golden
hour
studi
ethic
ref
written
inform
consent
receiv
particip
valid
proxi
famili
profession
directli
involv
studi
prior
inclus
studi
studi
approv
nation
research
ethic
servic
research
ethic
committe
refer
integr
research
applic
system
id
reco
golden
hour
studi
compli
guidelin
declar
helsinki
patient
categoris
hv
ec
mtbi
ec
stbi
ec
ec
injuri
patient
radiograph
clinicallyconfirm
injuri
histori
sign
head
trauma
current
clinic
signific
infect
individu
histori
neurolog
psychiatr
disord
exclud
mild
tbi
ec
includ
patient
confirm
head
trauma
glasgow
coma
scale
gc
score
sever
tbi
ec
includ
patient
gc
patient
gender
age
match
hv
patient
demograph
shown
tabl
blood
sampl
patient
categori
obtain
differ
time
point
post
injuri
hr
within
hr
hr
hr
blood
sampl
collect
hour
adher
studi
protocol
aim
collect
investig
tempor
chang
earli
later
time
point
follow
injuri
peripher
blood
sampl
taken
within
first
hour
hr
studi
patient
prehospit
clinician
west
midland
medic
emerg
respons
intervent
team
merit
follow
initi
intraven
access
scene
injuri
peripher
blood
sampl
taken
patient
subsequ
hospit
admiss
hr
hr
follow
trauma
collect
blood
sampl
left
room
temperatur
minut
prior
centrifug
rpm
minut
serum
aliquot
store
analysi
sampl
process
within
two
hour
venepunctur
proseek
multiplex
inflamm
olink
bioscienc
uppsala
sweden
use
perform
multiplex
proxim
assay
accord
manufactur
protocol
olink
bioscienc
uppsala
sweden
briefli
human
serum
togeth
mix
contain
antibodi
label
correspond
dna
oligonucleotid
incub
night
follow
extens
mix
contain
proxim
extens
assay
enzym
pcr
reagent
ad
follow
incub
plate
place
thermal
cycler
cycl
dna
amplif
dynam
array
ifc
fluidigm
ca
usa
prime
accord
manufactur
instruct
separ
plate
detect
mix
sampl
mix
togeth
load
prime
dynam
array
ifc
specif
primer
pair
inflammatori
protein
tabl
load
dynam
array
protein
express
programm
activ
fluidigm
biomark
reader
per
proseek
instruct
detail
detect
limit
reproduc
valid
found
olink
webpag
http
wwwolinkcomproductsproseekmultiplexdownloadsdatapackag
data
transfer
biomark
reader
olink
wizard
genex
softwar
olink
data
present
normal
protein
express
unit
npx
linear
scale
high
npx
correspond
high
protein
concentr
anova
bonferroni
correct
appli
pvalu
signific
adjust
comparison
within
group
tuckey
kramer
post
hoc
test
perform
comparison
group
across
time
dunnett
post
hoc
test
perform
